01.12.2017 | Research article | Ausgabe 1/2017 Open Access

Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
- Zeitschrift:
- BMC Cancer > Ausgabe 1/2017
Background
Methods
Statistical analysis
Results
Age at diagnosis
|
|
---|---|
median (min-max) [IQrange]
|
49.2 (26.7–76.6) [45.3–60.3]
|
<49
|
25 (46.3)
|
≥49
|
29 (53.7)
|
Stage
|
|
II
|
18 (33.3)
|
III
|
36 (66.7)
|
Grade
|
|
1–2
|
22 (40.7)
|
3
|
32 (59.3)
|
Ki-67
|
|
median (min-max) [IQrange]
|
70.0 (10.0–90.0) [43.7–80.0]
|
Chemotherapy
|
|
Sequential
|
47 (87.0)
|
Concomitant
|
7 (13.0)
|
pCR
|
|
No
|
37 (68.5)
|
Yes
|
17 (31.5)
|
BMI
|
|
median (min-max) [IQrange]
|
23.9 (17.5–41.6) [21.7–25.9]
|
< 25
|
31 (57.4)
|
≥ 25
|
23 (42.6)
|
γ-H2AX
|
|
Low
|
25 (46.3)
|
High
|
29 (53.7)
|
pChk1
|
|
Neg
|
16 (29.6)
|
Pos
|
38 (70.4)
|
BMI
|
Chi2 Test
|
||
---|---|---|---|
<25
|
≥25
|
p-value
|
|
N (%)
|
N (%)
|
||
Age at diagnosis
|
|||
< 49
|
20 (80.0)
|
5 (20.0)
|
0.002
|
≥ 49
|
11 (37.9)
|
18 (62.1)
|
|
Stage
|
|||
II
|
12 (66.7)
|
6 (33.3)
|
0.331
|
III
|
19 (52.8)
|
17 (47.2)
|
|
Grade
|
|||
1–2
|
13 (59.1)
|
9 (40.9)
|
0.836
|
3
|
18 (56.3)
|
14 (43.8)
|
|
Ki-67
|
|||
Low
|
15 (60.0)
|
10 (40.0)
|
0.721
|
High
|
16 (55.2)
|
13 (44.8)
|
|
Chemotherapy
|
|||
Sequential
|
27 (57.4)
|
20 (42.6)
|
0.999
a
|
Concomitant
|
4 (57.1)
|
3 (42.9)
|
|
pCR
|
|||
No
|
19 (51.4)
|
18 (48.6)
|
0.184
|
Yes
|
12 (70.6)
|
5 (29.4)
|
|
γ-H2AX
|
|||
Low
|
16 (64.0)
|
9 (36.0)
|
0.363
|
High
|
15 (51.7)
|
14 (48.3)
|
|
pChk1
|
|||
Neg
|
12 (75.0)
|
4 (25.0)
|
0.090
|
Pos
|
19 (50.0)
|
19 (50.0)
|
BMI < 25
|
BMI ≥ 25
|
|||||
---|---|---|---|---|---|---|
No pCR
|
pCR
|
Fisher’s Exact Test
|
No pCR
|
pCR
|
Fisher’s Exact Test
|
|
N (%)
|
N (%)
|
p-value
|
N (%)
|
N (%)
|
p-value
|
|
pCHK1
|
||||||
Neg
|
4 (33.3)
|
8 (66.7)
|
0.022
|
4 (100.0)
|
0 (0.0)
|
0.539
|
Pos
|
15 (78.9)
|
4 (21.1)
|
14 (73.7)
|
5 (26.3)
|
||
γ-H2AX
|
||||||
low
|
6 (37.5)
|
10 (62.5)
|
0.009
|
7 (77.8)
|
2 (22.2)
|
0.999
|
high
|
13 (86.7)
|
2 (13.3)
|
11 (78.6)
|
3 (21.4)
|
BMI < 25
|
||||||
Univariate logistic regression
|
Multivariate logistic regression
a
|
|||||
OR
|
95%CI
|
p-value
|
OR
|
95%CI
|
p-value
|
|
Stage
|
||||||
III vs II
|
0.37
|
0.08–1.81
|
0.220
|
|||
Grade
|
||||||
3 vs 1–2
|
0.98
|
0.23–4.25
|
0.981
|
|||
Ki-67
|
||||||
High vs Low
|
0.19
|
0.04–0.97
|
0.046
|
|||
γ-H2AX
|
||||||
High vs Low
|
10.83
|
1.79–65.55
|
0.009
|
10.83
|
1.79–65.55
|
0.009
|
pChk1
|
||||||
Pos vs Neg
|
7.50
|
1.47–38.28
|
0.015
|
|||
BMI ≥ 25
|
||||||
Univariate logistic regression
|
Multivariate logistic regression
|
|||||
OR
|
95%CI
|
p-value
|
OR
|
95%CI
|
p-value
|
|
Stage
|
||||||
III vs II
|
0.65
|
0.06–7.32
|
0.727
|
|||
Grade
|
||||||
3 vs 1–2
|
3.00
|
0.39–23.07
|
0.291
|
|||
Ki-67
|
||||||
High vs Low
|
0.25
|
0.02–2.70
|
0.253
|
|||
γ-H2AX
|
||||||
High vs Low
|
1.05
|
0.14–7.93
|
0.964
|
|||
pChk1
|
||||||
Pos vs Neg
|
Not applicable
|
BMI < 25
|
||||||
Univariate logistic regression
|
Multivariate logistic regression
a
|
|||||
OR
|
95%CI
|
p-value
|
OR
|
95%CI
|
p-value
|
|
Stage
|
||||||
III vs II
|
0.37
|
0.08–1.81
|
0.220
|
|||
Grade
|
||||||
3 vs 1–2
|
0.98
|
0.23–4.25
|
0.981
|
|||
Ki67
|
||||||
High vs Low
|
0.19
|
0.04–0.97
|
0.046
|
0.30
|
0.04–2.06
|
0.223
|
γ-H2AX
|
||||||
High vs Low
|
10.83
|
1.79–65.55
|
0.009
|
6.34
|
0.89–45.33
|
0.066
|
pChk1
|
||||||
Pos vs Neg
|
7.50
|
1.47–38.28
|
0.015
|
4.82
|
0.77–30.26
|
0.093
|
BMI ≥ 25
|
||||||
Univariate logistic regression
|
Multivariate logistic regression
|
|||||
OR
|
95%CI
|
p-value
|
OR
|
95%CI
|
p-value
|
|
Stage
|
||||||
III vs II
|
0.65
|
0.06–7.32
|
0.727
|
|||
Grade
|
||||||
3 vs 1–2
|
3.00
|
0.39–23.07
|
0.291
|
|||
Ki-67
|
||||||
High vs Low
|
0.25
|
0.02–2.70
|
0.253
|
|||
γ-H2AX
|
||||||
High vs Low
|
1.05
|
0.14–7.93
|
0.964
|
|||
pChk1
|
||||||
Pos vs Neg
|
Not applicable
|